NKGen Biotech Inc NKGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NKGN is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.35
- Day Range
- $1.22–1.34
- 52-Week Range
- $0.78–12.88
- Bid/Ask
- $1.25 / $1.38
- Market Cap
- $28.12 Mil
- Volume/Avg
- 147,724 / 3.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 63
- Website
- https://www.nkgenbiotech.com
Valuation
Metric
|
NKGN
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
NKGN
|
---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.05 |
Interest Coverage | −110.34 |
Quick Ratio
NKGN
Profitability
Metric
|
NKGN
|
---|---|
Return on Assets (Normalized) | −197.31% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NKGN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vdlsqhgqz | Ltbjk | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zxkykbcc | Cjsmjm | $108.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Srmbqhk | Ndxrrbb | $105.3 Bil | |
MRNA
| Moderna Inc | Lygfmpdbr | Xqmnp | $47.0 Bil | |
ARGX
| argenx SE ADR | Zvkxfpj | Bnrjr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rkysxldl | Skhx | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xnmbvpt | Vsstwt | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qghmzyl | Kmnqm | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kftzmmkpr | Fdnbsw | $12.6 Bil | |
INCY
| Incyte Corp | Bvknvvdlg | Mgrkgyx | $12.0 Bil |